Table 2.
Baseline demographics and clinical characteristics.
| NENs (n = 24) n (%) |
NETs (n = 6) n (%) |
NECs (n = 18) n (%) |
|
|---|---|---|---|
| Sex | |||
| Male | 11 (45.8) | 2 (33.3) | 9 (50.0) |
| Female | 13 (54.2) | 4 (66.7) | 9 (50.0) |
| Median age, years (range) | 57.0 (22.3~ 69.8) | 42.4 (27.0~ 62.0) | 57.9 (22.3~ 69.8) |
| ECOG PS score | |||
| 0 | 7 (29.2) | 3 (50.0) | 4 (22.2) |
| 1 | 17 (70.8) | 3 (50.0) | 14 (77.8) |
| Primary tumor location | |||
| Gastrointestinal | 10(41.7) | 1(16.7) | 9(50.0) |
| Pancreas | 7(29.2) | 4 (66.7) | 3(16.7) |
| Liver | 2(8.3) | 0 | 2(11.1) |
| Lung | 2(8.3) | 0 | 2 (11.1) |
| Others* | 3 (12.5) | 1(16.7) | 2(11.1) |
| Ki-67 (%), median | 60 | 10 | 70 |
| Previous line(s) of chemotherapy | |||
| 1 | 11 (45.8) | 1(16.7) | 10(55.6) |
| 2 | 4(16.7) | 2(33.3) | 2(11.1) |
| 3 | 6 (25.0) | 2(33.3) | 4(22.2) |
| ≥4 | 3(12.5) | 1(16.7) | 2(11.1) |
| Metastatic sites | |||
| Liver | 12(50.0) | 5(83.3) | 7(38.9) |
| Lung | 5(20.8) | 2(33.3) | 3(16.7) |
| Lymph nodes | 16(66.7) | 5(83.3) | 10(55.6) |
| Bone | 4(16.7) | 1(16.7) | 3(16.7) |
| Others | 8(33.3) | 3(50.0) | 5(27.8) |
| Previous treatment | |||
| Etoposide+platinum | 18(69.2) | 1(16.7) | 17(94.4) |
| Everolimus | 1(4.2) | 1(16.7) | 0 |
| VEGFR-TKI | 10(41.7) | 5(83.3) | 5(27.8) |
| Temozolomide | 6(25.0) | 3(50.0) | 3(16.7) |
| Others | 9(37.5) | 3(50.0) | 6(33.3) |
Pelvis (n = 1), cervix (n = 1), and sacroiliac (n = 1).
Abbreviations: NENs, neuroendocrine neoplasms; NETs, neuroendocrine tumors; NECs, neuroendocrine carcinomas; ECOG PS, Eastern Cooperative Oncology Group Performance Status; VEGFR-TKI, vascular endothelial growth factor receptor tyrosine kinase inhibitors.